DC
Therapeutic Areas
Concarlo Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| p27-Targeted Therapeutic | Drug-resistant metastatic breast cancer | Preclinical |
| p27-Targeted Therapeutic Platform | Ovarian cancer, Non-small cell lung cancer (NSCLC), Melanoma | Discovery/Preclinical |
Leadership Team at Concarlo Therapeutics
DS
Dr. Stacy Blain
Founder, Chief Executive Officer
DK
Dr. Krishna Allamneni
Chief Development Officer
KB
Kunal Bhatia
Interim Chief Financial Officer & Chief Business Officer
DG
Dr. Grace Chen
Director of Research
DD
Dr. Dominique Bridon
Peptide Advisor
DR
Dr. Robert DeVita
Chemistry Advisor